The comparative effect of Leukotriene receptor antagonist add on therapy and step up inhaled Corticosteroid in partially controlled asthma: An open-labeled randomized controlled trial
Main Article Content
Keywords
Asthma, asthma control, inhaled corticosteroids, leukotriene-receptor antagonists, lung function
Abstract
Background: No studies are comparing the impact of the add-on leukotriene-receptor antagonist (LTRA) with a step-up dose of inhaled corticosteroids (ICS) in partly controlled asthma patients with asthma control test (ACT) score ˂ 23.
Objective: To study the effect of LTRA add-on therapy in comparison to a step-up to medium dose of ICS in partially controlled asthma.
Methods: An open-labeled randomized controlled trial was conducted in asthma subjects with partly controlled asthma who had been in regular receipt of low dose ICS. All subjects were assessed for asthma using ACT, daytime and nighttime symptoms, rate of relievers used, spirometry, and impulse oscillometry (IOS) at 3 and 6 months. Subjects were randomized to receive daily oral LTRA 10 mg or step-up medium dose of ICS.
Results: Between June 2020 and January 2021, 50 participants were enrolled, all patients completing the study. After treatment, mean ACT scores were increased to more than 23 indicating well-controlled asthma in both groups, control being sustained throughout the whole 6-month study period (P ˂ 0.001). Within each group, ACT scores were improved by a minimal clinical important difference (MCID) ≥ 3 points at 6 months, compared to baseline values. There were significant decreases in nighttime and daytime symptoms, and the numbers of rescue relievers used in 4 weeks in both groups compared to baseline (P ˂ 0.001).
Conclusions: LTRA add-on therapy in partially controlled asthma patients is comparable with step-up to medium dose of ICS/LABA as regards asthma control.
References
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. [Internet]. [Accessed 2018 Apr 10]. Available from: http://www.ginasthma.org
3. Teeratakulpisarn J, Pairojkul S, Heng S. Survey of prevalence of asthma, Allergic rhinitis and eczema in schoolchildren from KhonKaen. An ISAAC (Study, International Study of Asthma and Allergic in Childhood). Asian Pac J. Allergy Immunol. 2000;18:4:187–194.
4. Murphy RC, Gijón MA. Biosynthesis and metabolism of leukotrienes. Biochem J. 2007.1;405(3):379–395. 10.1042/BJ20070289
5. Löfdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ. 1999;319(7202):87–90. 10.1136/bmj.319.7202.87
6. Beasley R, Harper J, Bird G, Maijers I, Weatherall M, Pavord ID. Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology. Am J Respir Crit Care Med. 2019;15;199(12):1471–1477. 10.1164/rccm.201810-1868CI
7. Sim D, Griffiths A, Armstrong D, Clarke C, Rodda C, Freezer N. Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma. Eur Respir J. 2003;21(4):633–636. 10.1183/09031936.03.00306302
8. Rogala B, Bożek A, Gluck J. Is there a relationship between asthma and diabetes? J Asthma. 2020;57(12):1332–1338. 10.1080/02770903.2019.1652642
9. Niyatiwatchanchai N, Chaiwong W, Pothirat C. The validity and reliability of the Thai version of the asthma control test. Asian Pac J Allergy Immunol. 2021 J [Online ahead of print].
10. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–338. 10.1183/09031936.05.00034805
11. King GG, Bates J, Berger KI, Calverley P, de Melo PL, Dellacà RL, et al. Technical standards for respiratory oscillometry. Eur Respir J. 2020;55(2):1900753. 10.1183/13993003.00753-2019
12. Johansson SA, Dahl R. A double-blind dose-response study of budesonide by inhalation in patients with bronchial asthma. Allergy. 1998;43:173–178. 10.1111/j.1398-9995.1988.tb00415.x
13. Virchow JC Jr, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med. 2000;162(2 Pt 1):578–585. 10.1164/ajrccm.162.2.9905041
14. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med. 1998;158(11):1213–1220. 10.1001/archinte.158.11.1213
15. Santanello NC, Barber BL, Reiss TF, Friedman BS, Juniper EF, Zhang J. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J. 1997;10:646–651.
16. Bisgaard H, Loland L, Anhoj J. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med.1999;160:1227–1231. 10.1164/ajrccm.160.4.9903004
17. Cottee AM, Seccombe LM, Thamrin C, King GG, Peters MJ, Farah CS. Bronchodilator Response Assessed by the Forced Oscillation Technique Identifies Poor Asthma Control With Greater Sensitivity Than Spirometry. Chest. 2020;157:1435–1441. 10.1016/j.chest.2019.12.035
18. Brashier B, Salvi S. Measuring lung function using sound waves: role of the forced oscillation technique and impulse oscillometry system. Breathe (Sheff). 2015;11(1):57–65. 10.1183/20734735.020514
19. Shi Y, Aledia AS, Galant SP, George SC. Peripheral airway impairment measured by oscillometry predicts loss of asthma control in children. J Allergy Clin Immunol. 2013;131(3):718–723. 10.1016/j.jaci.2012.09.022
20. Shi Y, Aledia AS, Tatavoosian AV, Vijayalakshmi S, Galant SP, George SC. Relating small airways to asthma control by using impulse oscillometry in children. J Allergy Clin Immunol. 2012;129(3):671–678. 10.1016/j.jaci.2011.11.002
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.